corrigenda
The renin–aldosterone axis in kidney transplant recipients and its association with allograft function and structure Kidney International (2015) 87, 243; doi:10.1038/ki.2014.253
Correction to: Kidney International (2014) 85, 404–415; doi:10.1038/ki.2013.278; published online 21 August 2013 For the above referenced article, one author was inadvertently not included. The additional author is: Behzad Najafian, Department of Pathology, University of Washington, Seattle, Washington, USA Also, there were errors with regard to Table 2. The correct Table 2 is shown below: Table 2 | Predictors of plasma renin activity (ng/ml/h) and plasma aldosterone (pg/ml) At baseline Plasma renin activity Estimate (95% CI) P-value
Variable Recipient age (years) Female recipient Caucasian recipient Recipient BMI (kg/m2) SBP (mm Hg) DBP (mm Hg) Live donor Donor age (years) Female donor Caucasian donor Cause of kidney disease DM HTN PCKD Other
0.004 0.81 0.60 0.003 0.005 0.01 0.48 0.03 0.66 0.26
( 0.12, 0.03) 0.75 0.47 ( 2.11, 1.17) ( 1.35, 0.28) o0.01 36.90 ( 73.97, 0.16) ( 0.15, 1.35) 0.12 11.15 ( 39.95, 62.26) ( 0.05, 0.06) 0.91 0.14 ( 3.55, 3.83) ( 0.024, 0.013) 0.56 0.37 ( 0.164, 0.90) ( 0.05, 0.02) 0.44 0.51 ( 3.05, 2.03) ( 1.10, 0.13) 0.13 43.41 ( 86.80, 0.03) ( 0.05, 0.01) 0.01 0.01 ( 1.53, 1.54) (0.14, 1.17) 0.01 15.82 ( 20.15, 51.79) ( 0.86, 0.34) 0.39 35.39 ( 76.65, 5.87)
Reference 0.28 ( 1.47, 0.90) 0.12 ( 0.96, 0.72) 0.57 ( 0.03, 1.17)
Smoking 0.26 Hyperlipidemia 0.24 Losartan 0.11 Thiazides 0.75 Loop diuretics 0.04 Tacrolimus þ rapamycin 0.13 Tacrolimus þ MMF 0.37 Tacrolimus þ MMF þ prednisone 0.79 CSA þ MMF 0.46 CSA þ MMF þ prednisone 0.74 24 h urine sodium (mEq/day) 0.002 24 h urine potassium (mEq/day) 0.004
( 0.47, ( 1.88, ( 0.59, ( 0.18, ( 0.57, ( 0.89, ( 1.33, ( 1.99, ( 1.44, ( 1.79, ( 0.01, ( 0.01,
1.00) 1.40) 0.37) 1.68) 0.66) 1.16) 0.60) 0.40) 0.53) 0.31) 0.001) 0.01)
Longitudinally
Plasma aldosterone Estimate (95% CI) P-value
Plasma renin activity Estimate (95% CI) P-value
0.57 0.05 0.67 0.94 0.57 0.69 0.05 0.99 0.39 0.09
0.02 0.65 0.38 0.03 0.006 0.05 0.93 0.02 1.11 0.44
Reference 0.64 23.08 ( 111.87, 65.70) 0.78 3.39 ( 63.60, 56.81) 0.06 18.50 ( 22.98, 59.97)
0.61 0.91 0.38
Reference 1.54 (0.02, 3.05) 0.36 ( 1.48, 0.77) 0.65 ( 0.23, 1.52)
0.48 20.89 ( 29.17, 70.95) 0.77 117.12 (3.32, 230.92) 0.66 5.59 ( 27.99, 39.17) 0.11 44.59 ( 20.48, 109.66) 0.89 6.96 ( 48.44, 34.52) 0.80 7.65 ( 65.62, 80.93) 0.45 0.65 ( 65.87, 67.16) 0.19 30.04 ( 52.28, 112.36) 0.36 1.13 ( 67.19, 69.44) 0.16 22.45 ( 94.30, 49.39) 0.13 0.31 ( 0.54, 0.08) 0.48 0.63 ( 0.11, 1.38)
0.41 0.04 0.74 0.18 0.74 0.84 0.98 0.47 0.97 0.54 0.01 0.10
0.96 0.62 1.61 0.003 0.17 0.57 0.05 0.23 0.76 0.66 0.01 0.02
Plasma aldosterone Estimate (95% CI) P-value
( 0.05, 0.01) 0.25 0.25 ( 1.39, 0.10) 0.09 25.59 ( 0.70, 1.47) 0.49 6.69 ( 0.04, 0.11) 0.37 3.15 ( 0.02, 0.03) 0.63 0.32 ( 0.09, 0.004) 0.03 1.74 ( 1.81, 0.05) 0.04 33.3 ( 0.05, 0.01) 0.21 0.32 (0.36, 1.86) o0.01 16.59 ( 0.44, 1.31) 0.32 10.34
( 1.47, 0.97) ( 52.62, 1.43) ( 46.52, 33.15) (0.37, 5.93) ( 1.15, 0.51) (0.27, 3.21) ( 65.35, 1.25) ( 1.48, 0.85) ( 10.96, 44.15) ( 42.56, 21.87)
Reference 0.05 17.96 ( 75.43, 39.51) 0.53 7.74 ( 34.11, 49.59) 0.15 5.09 ( 26.77, 36.94)
0.69 0.06 0.74 0.03 0.45 0.02 0.04 0.59 0.24 0.53
0.54 0.72 0.75
( 1.95, 0.03) 0.06 20.37 ( 58.06, 17.31) 0.29 ( 2.34, 1.11) 0.48 46.25 ( 20.40, 112.89) 0.17 (0.90, 2.31) o0.01 14.73 ( 40.57, 11.11) 0.26 ( 1.29, 1.29) 0.99 24.21 ( 23.88, 72.29) 0.32 ( 0.68, 1.02) 0.69 25.64 ( 56.97, 5.69) 0.11 ( 0.95, 2.09) 0.46 1.98 ( 54.92, 58.88) 0.95 ( 1.43, 1.34) 0.95 1.27 ( 52.26, 49.73) 0.96 ( 1.59, 2.04) 0.81 47.03 ( 19.81, 113.86) 0.17 ( 0.66, 2.18) 0.29 27.39 ( 79.82, 25.04) 0.30 ( 0.87, 2.18) 0.40 18.64 ( 75.46, 38.18) 0.52 ( 0.01, 0.002) o0.01 0.45 ( 0.57, 0.32) o0.01 (0.003, 0.03) 0.01 0.81 (0.36, 1.26) o0.01
Abbreviations: ACR, albumin–creatinine ratio; BMI, body mass index; CI, confidence interval; CKD, chronic kidney disease; CSA, cyclosporine; DBP, diastolic blood pressure; DM, diabetes mellitus; HTN, hypertension; MMF, mycophenolate mofetil; PCKD, polycystic kidney disease; SBP, systolic blood pressure.
Microalbuminuria: target for renoprotective therapy PRO Kidney International (2015) 87, 243–244; doi:10.1038/ki.2014.321
Correction to: Kidney International (2014) 86, 40–49; doi:10.1038/ki.2013.490 The legend of Figure 4 was mislabeled. Figure 4b and c show the reduction in heart failure or vascular events consequent to blood pressure or LDL cholesterol reduction.
Kidney International (2015), 242–244
243
The renin–aldosterone axis in kidney transplant recipients and its association with allograft function and structure Kidney International (2015) 87, 243; doi:10.1038/ki.2014.253
Correction to: Kidney International (2014) 85, 404–415; doi:10.1038/ki.2013.278; published online 21 August 2013 For the above referenced article, one author was inadvertently not included. The additional author is: Behzad Najafian, Department of Pathology, University of Washington, Seattle, Washington, USA Also, there were errors with regard to Table 2. The correct Table 2 is shown below: Table 2 | Predictors of plasma renin activity (ng/ml/h) and plasma aldosterone (pg/ml) At baseline Plasma renin activity Estimate (95% CI) P-value
Variable Recipient age (years) Female recipient Caucasian recipient Recipient BMI (kg/m2) SBP (mm Hg) DBP (mm Hg) Live donor Donor age (years) Female donor Caucasian donor Cause of kidney disease DM HTN PCKD Other
0.004 0.81 0.60 0.003 0.005 0.01 0.48 0.03 0.66 0.26
( 0.12, 0.03) 0.75 0.47 ( 2.11, 1.17) ( 1.35, 0.28) o0.01 36.90 ( 73.97, 0.16) ( 0.15, 1.35) 0.12 11.15 ( 39.95, 62.26) ( 0.05, 0.06) 0.91 0.14 ( 3.55, 3.83) ( 0.024, 0.013) 0.56 0.37 ( 0.164, 0.90) ( 0.05, 0.02) 0.44 0.51 ( 3.05, 2.03) ( 1.10, 0.13) 0.13 43.41 ( 86.80, 0.03) ( 0.05, 0.01) 0.01 0.01 ( 1.53, 1.54) (0.14, 1.17) 0.01 15.82 ( 20.15, 51.79) ( 0.86, 0.34) 0.39 35.39 ( 76.65, 5.87)
Reference 0.28 ( 1.47, 0.90) 0.12 ( 0.96, 0.72) 0.57 ( 0.03, 1.17)
Smoking 0.26 Hyperlipidemia 0.24 Losartan 0.11 Thiazides 0.75 Loop diuretics 0.04 Tacrolimus þ rapamycin 0.13 Tacrolimus þ MMF 0.37 Tacrolimus þ MMF þ prednisone 0.79 CSA þ MMF 0.46 CSA þ MMF þ prednisone 0.74 24 h urine sodium (mEq/day) 0.002 24 h urine potassium (mEq/day) 0.004
( 0.47, ( 1.88, ( 0.59, ( 0.18, ( 0.57, ( 0.89, ( 1.33, ( 1.99, ( 1.44, ( 1.79, ( 0.01, ( 0.01,
1.00) 1.40) 0.37) 1.68) 0.66) 1.16) 0.60) 0.40) 0.53) 0.31) 0.001) 0.01)
Longitudinally
Plasma aldosterone Estimate (95% CI) P-value
Plasma renin activity Estimate (95% CI) P-value
0.57 0.05 0.67 0.94 0.57 0.69 0.05 0.99 0.39 0.09
0.02 0.65 0.38 0.03 0.006 0.05 0.93 0.02 1.11 0.44
Reference 0.64 23.08 ( 111.87, 65.70) 0.78 3.39 ( 63.60, 56.81) 0.06 18.50 ( 22.98, 59.97)
0.61 0.91 0.38
Reference 1.54 (0.02, 3.05) 0.36 ( 1.48, 0.77) 0.65 ( 0.23, 1.52)
0.48 20.89 ( 29.17, 70.95) 0.77 117.12 (3.32, 230.92) 0.66 5.59 ( 27.99, 39.17) 0.11 44.59 ( 20.48, 109.66) 0.89 6.96 ( 48.44, 34.52) 0.80 7.65 ( 65.62, 80.93) 0.45 0.65 ( 65.87, 67.16) 0.19 30.04 ( 52.28, 112.36) 0.36 1.13 ( 67.19, 69.44) 0.16 22.45 ( 94.30, 49.39) 0.13 0.31 ( 0.54, 0.08) 0.48 0.63 ( 0.11, 1.38)
0.41 0.04 0.74 0.18 0.74 0.84 0.98 0.47 0.97 0.54 0.01 0.10
0.96 0.62 1.61 0.003 0.17 0.57 0.05 0.23 0.76 0.66 0.01 0.02
Plasma aldosterone Estimate (95% CI) P-value
( 0.05, 0.01) 0.25 0.25 ( 1.39, 0.10) 0.09 25.59 ( 0.70, 1.47) 0.49 6.69 ( 0.04, 0.11) 0.37 3.15 ( 0.02, 0.03) 0.63 0.32 ( 0.09, 0.004) 0.03 1.74 ( 1.81, 0.05) 0.04 33.3 ( 0.05, 0.01) 0.21 0.32 (0.36, 1.86) o0.01 16.59 ( 0.44, 1.31) 0.32 10.34
( 1.47, 0.97) ( 52.62, 1.43) ( 46.52, 33.15) (0.37, 5.93) ( 1.15, 0.51) (0.27, 3.21) ( 65.35, 1.25) ( 1.48, 0.85) ( 10.96, 44.15) ( 42.56, 21.87)
Reference 0.05 17.96 ( 75.43, 39.51) 0.53 7.74 ( 34.11, 49.59) 0.15 5.09 ( 26.77, 36.94)
0.69 0.06 0.74 0.03 0.45 0.02 0.04 0.59 0.24 0.53
0.54 0.72 0.75
( 1.95, 0.03) 0.06 20.37 ( 58.06, 17.31) 0.29 ( 2.34, 1.11) 0.48 46.25 ( 20.40, 112.89) 0.17 (0.90, 2.31) o0.01 14.73 ( 40.57, 11.11) 0.26 ( 1.29, 1.29) 0.99 24.21 ( 23.88, 72.29) 0.32 ( 0.68, 1.02) 0.69 25.64 ( 56.97, 5.69) 0.11 ( 0.95, 2.09) 0.46 1.98 ( 54.92, 58.88) 0.95 ( 1.43, 1.34) 0.95 1.27 ( 52.26, 49.73) 0.96 ( 1.59, 2.04) 0.81 47.03 ( 19.81, 113.86) 0.17 ( 0.66, 2.18) 0.29 27.39 ( 79.82, 25.04) 0.30 ( 0.87, 2.18) 0.40 18.64 ( 75.46, 38.18) 0.52 ( 0.01, 0.002) o0.01 0.45 ( 0.57, 0.32) o0.01 (0.003, 0.03) 0.01 0.81 (0.36, 1.26) o0.01
Abbreviations: ACR, albumin–creatinine ratio; BMI, body mass index; CI, confidence interval; CKD, chronic kidney disease; CSA, cyclosporine; DBP, diastolic blood pressure; DM, diabetes mellitus; HTN, hypertension; MMF, mycophenolate mofetil; PCKD, polycystic kidney disease; SBP, systolic blood pressure.
Microalbuminuria: target for renoprotective therapy PRO Kidney International (2015) 87, 243–244; doi:10.1038/ki.2014.321
Correction to: Kidney International (2014) 86, 40–49; doi:10.1038/ki.2013.490 The legend of Figure 4 was mislabeled. Figure 4b and c show the reduction in heart failure or vascular events consequent to blood pressure or LDL cholesterol reduction.
Kidney International (2015), 242–244
243
